Does Strict Regulation of Capital Markets Enhance Firms' Ability to Spend on R&D?
Frontiers in Business, Economics and Management · 2025
DOI: 10.54097/0veppd85 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Business, Economics and Management, 2025. Verfasst von Zhenna Huang und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
China's updated Securities Law aims to promote enterprise value creation, optimize resource allocation, and foster high-quality economic development, with a core focus on protecting small and medium-sized investors, strengthening information disclosure, and enhancing financial market stability. This study employs the Difference-in-Differences (DID) method to empirically analyze the impact of the new law on firms' R&D investment. Results show that stringent capital market regulation significantly boosts R&D expenditure, particularly in heavily polluting industries and non-manufacturing sectors. The mechanism analysis reveals that improved disclosure quality and reduced financing constraints (measured by the SA index) mediate this effect, while internal control quality and equity concentration moderate the relationship. These findings provide theoretical and empirical support for optimizing capital market regulations to stimulate corporate innovation.
Zitieren
APA
Huang, Z., Jiang, L., & Hong, W. (2025). Does Strict Regulation of Capital Markets Enhance Firms' Ability to Spend on R&D?. Frontiers in Business, Economics and Management. https://doi.org/10.54097/0veppd85
Vancouver
Huang Z, Jiang L, Hong W. Does Strict Regulation of Capital Markets Enhance Firms' Ability to Spend on R&D?. Frontiers in Business, Economics and Management. 2025. doi:10.54097/0veppd85
BibTeX
@article{Huang2025,
author = {Huang, Zhenna and Jiang, LIna and Hong, Weixin},
title = {Does Strict Regulation of Capital Markets Enhance Firms' Ability to Spend on R&D?},
journal = {Frontiers in Business, Economics and Management},
year = {2025},
doi = {10.54097/0veppd85}
}
EUVIMED